PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

NEW YORK, Feb.  11, 2020  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company’s majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its EsoGuard™ Esophageal DNA Test on esophageal samples collected using its EsoCheck™ Cell Collection Device in a prevalent well-defined group of patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease (GERD).

U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test

NEW YORK, Jan.  13, 2020  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) of compliance with Nasdaq Listing Rule 5550(a)(2) after 10 consecutive days with a closing bid price of at least $1 per share.

PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance

First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer

PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test

NEW YORK, Dec.  13, 2019  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its CarpX™ first-in-human (FIH) 510(k) clinical safety study.

PAVmed Provides Update on CarpX™ Clinical Safety Study

PAVmed Has Multiple Paths To Growth

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q3 2019 Results - Earnings Call Transcript

Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time

PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update

Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology

PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products

Unprecedented six-month maintenance-free implant duration achieved

PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones

PAVM has a market cap of $35 million with one FDA approved device and another expected by early 2020. The TAM for these devices is $3B+ in the U.S. alone.

PAVmed - Small Medical Device Company 'PAV'ing The Way For Future Price Gains

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2019 Results - Earnings Call Transcript

Conference call to be held on September 5, 2019 at 4:30 p.m. Eastern time

PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update

NEW YORK, Aug.  21, 2019  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 10,335,189 which covers the technology underlying PAVmed’s CarpX minimally invasive device developed to treat carpal tunnel syndrome. The patent, assigned to PAVmed at its founding, lists Lishan Aklog, M.D., PAVmed’s Chairman & CEO, and Brian J. deGuzman, M.D., its Chief Medical Officer, as inventors.

USPTO Grants PAVmed Patent Covering its CarpX™ Device

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2019 Results - Earnings Call Transcript

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2018 Results and Business Update- Earnings Call Transcript

News for PAVmed Stock (PAVM)